Phathom Pharmaceuticals shares rise 11.41% intraday after reporting Q2 revenue beating estimates.
ByAinvest
Thursday, Aug 7, 2025 10:02 am ET1min read
PHAT--
Phathom Pharmaceuticals, Inc. rose 11.41% in intraday trading, with the company reporting its second-quarter 2025 earnings, which beat estimates. The company also announced that its heartburn drug, Vquezna, has received regulatory exclusivity in the FDA Orange Book update, confirming 10 years of exclusivity through May 3, 2032. Additionally, the company appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet